All In Biotech

Drug Trial Radar · NCT05016895

REACH2: Implementation Research on Bi-Annual Mass Distribution of Azithromycin to Children 1-11 Months in Côte d'Ivoire

The Resiliency Through Azithromycin for Children Project: Implementation Research on Bi-Annual Mass Distribution of Azithromycin to Children 1-11 Months in Côte d'Ivoire

Last checked: Nov 19, 2026Latest source record: Mar 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

767,535

Actual

Start

Aug 27, 2021

Primary completion

Jun 30, 2024

Study completion Jul 31, 2024

Sponsor

Lead sponsor
FHI 360Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ministry of Health, Ivory Coast
First posted
Aug 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Health services research
FDA-regulated drug
No
Who can join
All sexes, from 1 month, up to 11 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

REACH2 is a three-year implementation research study designed to examine the implementation through a mass drug administration platform of bi-annual single-dose azithromycin to reduce child mortality among children ages 1 to 11 months who reside in high child mortality settings.

Conditions

  • Child Mortality

Interventions

  • Single-dose azithromycinDrug

    Bi-annual mass, community-based distribution of single-dose azithromycin to children ages 1 to 11 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. % of eligible population covered by interventionTime frame: three years
  2. Infant mortality rateTime frame: three years
  3. Implementation fidelityTime frame: three years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • FHI 360

    Abidjan, Côte d’Ivoire

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.